Gilead Sciences is a biopharmaceutical company focused on discovering, developing and delivering innovative therapeutics for people with life-threatening diseases. The company says its work spans more than 35 countries and centers on virology, oncology, and inflammation.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Lenacapavir was launched in Zimbabwe in February 2026 as Kenya became the fourth African country to start administering the twice-yearly HIV prevention injection. The rollout follows launches in Eswatini and Zambia in December 2025, five months after US FDA approval.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.
Gilead Sciences has agreed a global licensing deal worth up to $1.5 billion with China's Genhouse Bio for its synthetic lethal cancer candidate GH31, a MAT2A inhibitor with IND clearance in the USA and China.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
South Africa is working to identify local manufacturers for lenacapavir, a twice-yearly injectable HIV prevention drug that showed near-perfect efficacy in clinical trials. Kenya has already received 21,000 doses of the medication.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07601243 |
Study of GS-2426 in Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07580482 |
The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral |
COMPLETED | NA |
| NCT07560046 |
Combating Related Epidemics in HCV |
NOT_YET_RECRUITING | PHASE4 |
| NCT07546812 |
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas |
RECRUITING | PHASE2 |
| NCT07530263 |
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07527858 |
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07476339 |
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE |
NOT_YET_RECRUITING | PHASE4 |
| NCT07474558 |
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates |
NOT_YET_RECRUITING | PHASE2 |
| NCT07473778 |
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention |
RECRUITING | |
| NCT07462611 |
HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study |
NOT_YET_RECRUITING | NA |
